E Kaufman1,2, C de Castro3, T Williamson4, B Lessard3, M Munoz3, M H Mayrand5, A N Burchell6,7, M B Klein3,7, L Charest8, M Auger9, V Marcus9, F Coutlée3,10, A de Pokomandy1,3,7. 1. Department of Family Medicine, McGill University, Montreal, QC. 2. Cumming School of Medicine, University of Calgary, Calgary, AB. 3. Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC. 4. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB. 5. Départements d'obstétrique-gynécologie et de médecine sociale et préventive, Centre hospitalier de l'Université de Montréal and Université de Montréal, Montreal, QC. 6. Department of Family and Community Medicine and Centre for Urban Health Solutions, St. Michael's Hospital, and Department of Family and Community Medicine and Dalla Lana School of Public Health, University of Toronto, Toronto, ON. 7. Canadian Institutes of Health Research, Canadian HIV Trials Network, Vancouver, BC. 8. Clinique médicale l'Actuel, Montreal, QC. 9. Department of Pathology, McGill University, and McGill University Health Centre, Montreal, QC. 10. Département de microbiologie, infectiologie, et immunologie, Centre hospitalier de l'Université de Montréal and Université de Montréal, Montreal, QC.
Abstract
Background: Anal cancer is potentially preventable through screening. For screening to be implemented, the screening procedures must be acceptable to the affected population. The objective of the present study was to measure the acceptability of currently available anal cancer screening tests in a population of women living with hiv who had experienced the tests. Methods: The evva study ("Evaluation of Human Immunodeficiency Virus, Human Papillomavirus, and Anal Intraepithelial Neoplasia in Women") is a prospective cohort study of adult women living with hiv in Montreal, Quebec. Participants were screened with cervical or anal hpv testing and cervical or anal cytology every 6 months for 2 years. High-resolution anoscopy (hra) and digital anal rectal examination (dare) were also performed systematically, with biopsies, at baseline and at 2 years. An acceptability questionnaire was administered at the final visit or at study withdrawal. Results: Of 124 women who completed the acceptability questionnaire, most considered screening "an absolute necessity" in routine care for all women living with hiv [77%; 95% confidence interval (ci): 69% to 84%]. Yearly anal cytology or anal hpv testing was considered very acceptable by 81% (95% ci: 73% to 88%); hra every 2 years was considered very acceptable by 84% (95% ci: 77% to 90%); and yearly dare was considered very acceptable by 87% (95% ci: 79% to 92%). Acceptability increased to more than 95% with a longer proposed time interval. Pain was the main reason for lower acceptability. Conclusions: Most participating women considered anal cancer screening necessary and very acceptable. Longer screening intervals and adequate pain management could further increase the acceptability of repeated screening. 2020 Multimed Inc.
Background: Anal cancer is potentially preventable through screening. For screening to be implemented, the screening procedures must be acceptable to the affected population. The objective of the present study was to measure the acceptability of currently available anal cancer screening tests in a population of women living with hiv who had experienced the tests. Methods: The evva study ("Evaluation of Human Immunodeficiency Virus, Human Papillomavirus, and Anal Intraepithelial Neoplasia in Women") is a prospective cohort study of adult women living with hiv in Montreal, Quebec. Participants were screened with cervical or anal hpv testing and cervical or anal cytology every 6 months for 2 years. High-resolution anoscopy (hra) and digital anal rectal examination (dare) were also performed systematically, with biopsies, at baseline and at 2 years. An acceptability questionnaire was administered at the final visit or at study withdrawal. Results: Of 124 women who completed the acceptability questionnaire, most considered screening "an absolute necessity" in routine care for all women living with hiv [77%; 95% confidence interval (ci): 69% to 84%]. Yearly anal cytology or anal hpv testing was considered very acceptable by 81% (95% ci: 73% to 88%); hra every 2 years was considered very acceptable by 84% (95% ci: 77% to 90%); and yearly dare was considered very acceptable by 87% (95% ci: 79% to 92%). Acceptability increased to more than 95% with a longer proposed time interval. Pain was the main reason for lower acceptability. Conclusions: Most participating women considered anal cancer screening necessary and very acceptable. Longer screening intervals and adequate pain management could further increase the acceptability of repeated screening. 2020 Multimed Inc.
Entities:
Keywords:
anal cancer; cancer prevention; hiv; hpv; human papillomavirus; screening acceptability; women
Authors: Stefan Esser; Alexander Kreuter; Mark Oette; Andrea Gingelmaier; Franz Mosthaf; Marie-Luise Sautter-Bihl; Johannes Jongen; Norbert H Brockmeyer; Gerd Eldering; Jochen Swoboda; Nils Postel; Olaf Degen; Horst Schalk; Arne Jessen; Heribert Knechten; Jan Thoden; Hans-Jürgen Stellbrink; Armin Schafberger; Ulrike Wieland Journal: J Dtsch Dermatol Ges Date: 2015-12 Impact factor: 5.584
Authors: James Dickinson; Eva Tsakonas; Sarah Conner Gorber; Gabriela Lewin; Elizabeth Shaw; Harminder Singh; Michel Joffres; Richard Birtwhistle; Marcello Tonelli; Verna Mai; Meg McLachlin Journal: CMAJ Date: 2013-01-07 Impact factor: 8.262
Authors: T R H Read; L Vodstrcil; A E Grulich; C Farmer; C S Bradshaw; M Y Chen; S Tabrizi; J S Hocking; J Anderson; C K Fairley Journal: HIV Med Date: 2013-04-16 Impact factor: 3.180
Authors: Elaina Kaufman; Tyler Williamson; Marie-Hélène Mayrand; Ann N Burchell; Marina Klein; Louise Charest; Sophie Rodrigues-Coutlée; François Coutlée; Alexandra de Pokomandy Journal: PLoS One Date: 2022-05-19 Impact factor: 3.752
Authors: Robin T Higashi; Serena A Rodriguez; Andrea C Betts; Jasmin A Tiro; Amneris E Luque; Rachel Rivera; Arti Barnes Journal: AIDS Care Date: 2021-02-17